MX2017003377A - Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado. - Google Patents

Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado.

Info

Publication number
MX2017003377A
MX2017003377A MX2017003377A MX2017003377A MX2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A MX 2017003377 A MX2017003377 A MX 2017003377A
Authority
MX
Mexico
Prior art keywords
recombinant plasmid
codon
humans
peripheral nerve
regeneration
Prior art date
Application number
MX2017003377A
Other languages
English (en)
Other versions
MX385916B (es
Inventor
Vadimovich Deev Roman
Aleksandrovich ISAEV Artur
Yadigerovich Bozo Ilya
Anatolyevich Rizvanov Albert
Faridovich MASGUTOV Ruslan
Andreevich Bogov Aleksei
Ildusovich SALAFUTDINOV Ilnur
Leonidovich Plaksa Igor
Alekseevich BOGOV Andrei
Original Assignee
Nextgen Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextgen Company Ltd filed Critical Nextgen Company Ltd
Publication of MX2017003377A publication Critical patent/MX2017003377A/es
Publication of MX385916B publication Critical patent/MX385916B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a ingeniería génica así como medicina, específicamente, neurocirugía y traumatología. La invención describe una estructura terapéutica de gen que codifica un factor de crecimiento endotelial vascular (VEGF) y un factor de crecimiento de fibroblasto (FGF-2). El plásmido recombinante con codón optimizado es el componente activo de la estructura terapéutica de gen que codifica ambos factores. Una estructura terapéutica de gen podría ser administrada directamente en un nervio dañado y los tejidos paraneurales tanto en períodos intraoperativos como pos-operativos. La invención se propone para estimular la regeneración de nervios. La invención significativamente mejora los resultados de un tratamiento de nervio periférico lesionado.
MX2017003377A 2014-09-16 2015-08-27 Plásmido recombinante con codón optimizado, técnica de estimulacion para regeneración de nervio periférico, modalidad de tratamiento para nervio humano dañado. MX385916B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2014137218/10A RU2558294C1 (ru) 2014-09-16 2014-09-16 Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека
PCT/RU2015/000545 WO2016163912A1 (ru) 2014-09-16 2015-08-27 Кодон-оптимизированная рекомбинантная плазмида, способ стимуляции регенерации периферического нерва, способ лечения поврежденного нерва человека

Publications (2)

Publication Number Publication Date
MX2017003377A true MX2017003377A (es) 2017-11-22
MX385916B MX385916B (es) 2025-03-18

Family

ID=53762789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003377A MX385916B (es) 2014-09-16 2015-08-27 Plásmido recombinante con codón optimizado, técnica de estimulacion para regeneración de nervio periférico, modalidad de tratamiento para nervio humano dañado.

Country Status (10)

Country Link
US (2) US20170189488A1 (es)
EP (1) EP3196307B1 (es)
JP (1) JP6540797B2 (es)
CN (1) CN107087417A (es)
AU (1) AU2015390821B2 (es)
BR (1) BR112017005310B1 (es)
CA (1) CA2960371C (es)
MX (1) MX385916B (es)
RU (1) RU2558294C1 (es)
WO (1) WO2016163912A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2614665C1 (ru) * 2015-12-18 2017-03-28 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Способ стимуляции репаративного ангиогенеза и регенерации соединительной ткани, при её повреждении, методом генной терапии с использованием видоспецифичных генов белковых факторов vegf и fgf2, в ветеринарии, и генетическая конструкция для реализации заявленного способа
WO2017203356A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
RU2769474C2 (ru) * 2017-01-20 2022-04-01 Атара Байотерапьютикс, Инк. Способы лечения рассеянного склероза с использованием аутологичных т-клеток
RU2762855C1 (ru) * 2021-04-08 2021-12-23 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генно-клеточный везикулярный терапевтический препарат и способ терапии рассеянного склероза посредством трансплантации генно-клеточного везикулярного терапевтического препарата

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005232665B2 (en) * 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
RU2459630C1 (ru) * 2011-04-27 2012-08-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) Федеральный Университет" (ФГАОУ ВПО КФУ) Способ стимулирования нейрогенерации с помощью генетических конструкций
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
RU2517117C2 (ru) * 2012-11-26 2014-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Казанский ГМУ Минздравсоцразвития России) Способ стимулирования регенерации нерва с помощью наноструктурированного матрикса и генетических конструкций

Also Published As

Publication number Publication date
CA2960371A1 (en) 2016-10-13
CA2960371C (en) 2019-06-25
AU2015390821B2 (en) 2018-08-09
RU2558294C1 (ru) 2015-07-27
MX385916B (es) 2025-03-18
CN107087417A (zh) 2017-08-22
BR112017005310A2 (pt) 2018-02-14
WO2016163912A1 (ru) 2016-10-13
EP3196307A1 (en) 2017-07-26
BR112017005310B1 (pt) 2023-10-03
JP2017532021A (ja) 2017-11-02
US20170189488A1 (en) 2017-07-06
US10434145B2 (en) 2019-10-08
US20170319658A1 (en) 2017-11-09
JP6540797B2 (ja) 2019-07-10
AU2015390821A1 (en) 2017-05-04
EP3196307B1 (en) 2018-12-26
EP3196307A4 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
MX2017003377A (es) Plasmido recombinante con codon optimizado, tecnica de estimulacion para regenracion de nervio periferico, modalidad de tratamiento para nervio humano dañado.
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
NZ704579A (en) Nasal stimulation devices and methods
WO2020176693A3 (en) Methods for treating map3k8 positive cancers
WO2015130891A3 (en) Ultraviolet phototherapy apparatuses and methods
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
WO2011112773A3 (en) Modular stimulator for treatment of back pain, implantable rf ablation system and methods of use
CL2015001700A1 (es) Tratamiento de trastornos del ritmo circadiano
MX2015003643A (es) Metodo para tratar el cancer.
SG10201902664RA (en) Combination therapy for treating cancer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
AR090972A1 (es) Metodo para tratar amd en pacientes resistentes a la terapia anti-vegf
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
PH12014500301A1 (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
IL267958A (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
WO2011133957A3 (en) Devices for delivering neuro-electro-adaptive therapy (neat)
EA201591638A1 (ru) Совместное введение стероидов и золедроновой кислоты для профилактики и лечения остеоартрита
WO2016060917A3 (en) Formulations for histatin therapeutics
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.